A novel homozygous nonsense mutation E135* in the type II 3β-hydroxysteroid dehydrogenase gene in a girl with salt-losing congenital adrenal hyperplasia

✍ Scribed by Suemi Marui; Isabel M. Torrealba; Alan J. Russell; Ana C. Latronico; Roger G. Sutcliffe; Berenice B. Mendonca

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 80 KB
• Volume: 12
• Category: Article
• ISSN: 1059-7794
• DOI: 10.1002/(sici)1098-1004(1998)12:2<139::aid-humu19>3.0.co;2-4

✦ Synopsis

Mutations in the 3 -hydroxysteroid dehydrogenase (3 -HSD) type II gene have been reported in a small number of affected females. We report a 46,XX girl born to consanguineous parents from Chile. At birth, she had normal but hyperpigmented female external genitalia. At 60 days she presented salt loss. At 20 months, the diagnosis of classic salt-losing 3 -HSD deficiency was made based on an elevated serum 17-hydroxypregnenolone concentration and a high 17-hydroxypregnenolone/ 17-hydroxyprogesterone ratio. Genomic DNA was amplified by PCR and screened for mutations by denaturing gradient gel electrophoresis and directly sequenced. A novel homozygous E135* mutation was found in the 3 -HSD type II gene of the patient while her parents were heterozygotes. This novel nonsense homozygous E135* mutation led to encode a predicted truncated 134 amino acid protein instead of the native 371 amino acid 3 -HSD type II protein. This predicted product is consistent with the severe 3 -HSD deficiency in this girl.